Entact Bio makes its Series A debut with $81M to launch protein enhancement platform
Entact Bio has secured $81 million in a Series A round to push forward its platform for developing therapies that can enhance the function of proteins that are crucial to fight disease.
Known as enhancement-targeting chimeric (ENTAC) molecules, Entact’s idea is to use the drug platform in the treatment of certain cancers, inflammatory diseases and rare genetic disorders associated with haploinsufficiences, in which patients have too little of a protein in their cells. Because ENTACs are small molecules, they can be orally delivered and are much cheaper to manufacture.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.